Complete financial analysis of Daré Bioscience, Inc. (DARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Daré Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Mishra Dhatu Nigam Limited (MIDHANI.NS) Income Statement Analysis – Financial Results
- Tuan Sing Holdings Limited (T24.SI) Income Statement Analysis – Financial Results
- Aisin Corporation (ASEKY) Income Statement Analysis – Financial Results
- Semper Paratus Acquisition Corporation (LGSTU) Income Statement Analysis – Financial Results
- Ovostar Union Public Company Limited (OVO.WA) Income Statement Analysis – Financial Results
Daré Bioscience, Inc. (DARE)
About Daré Bioscience, Inc.
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.81M | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 766.00K | 0.00 | 80.00K | 6.00K | 625.00K | 305.00K |
| Cost of Revenue | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 0.00 | 400.00K | 192.00K | 0.00 | 0.00 | 0.00 | 363.00K |
| Gross Profit | 2.77M | 9.95M | -26.41K | -43.23K | -11.14K | -2.44K | 0.00 | 366.00K | -192.00K | 80.00K | 6.00K | 625.00K | -58.00K |
| Gross Profit Ratio | 98.63% | 99.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.78% | 0.00% | 100.00% | 100.00% | 100.00% | -19.02% |
| Research & Development | 21.54M | 30.04M | 30.62M | 20.77M | 8.55M | 6.41M | 984.75K | 27.57M | 25.95M | 11.77M | 9.70M | 15.81M | 13.49M |
| General & Administrative | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.11M | 11.24M | 8.45M | 6.63M | 5.80M | 5.28M | 2.70M | 10.36M | 11.22M | 8.59M | 6.17M | 6.39M | 5.34M |
| Other Expenses | 0.00 | 100.00K | 2.52K | 1.51K | 81.05K | 143.50K | 7.49B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 33.61M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 18.82M |
| Cost & Expenses | 33.75M | 41.39M | 39.07M | 27.40M | 14.34M | 11.69M | 3.69M | 37.92M | 37.17M | 20.36M | 15.87M | 22.20M | 19.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 10.00K | 9.00K | 2.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 322.63K | 2.24M | 2.43M | 1.08M | 1.49M | 567.00K | 26.00K |
| Depreciation & Amortization | 38.36K | 47.62K | 26.41K | 43.23K | 11.14K | 2.44K | 2.73M | 261.00K | 192.00K | 126.00K | 197.00K | 346.00K | 363.00K |
| EBITDA | -30.90M | -31.36M | -39.04M | -27.36M | -14.33M | -11.69M | -11.18M | -36.81M | -36.97M | -22.13M | -15.46M | -21.19M | -18.55M |
| EBITDA Ratio | -1,100.53% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,805.09% | 0.00% | -25,180.00% | -261,016.67% | -3,396.32% | -6,082.95% |
| Operating Income | -30.84M | -31.39M | -39.07M | -27.40M | -14.34M | -16.88M | -11.18M | -37.15M | -37.17M | -20.28M | -15.86M | -21.58M | -18.88M |
| Operating Income Ratio | -1,098.33% | -313.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,850.39% | 0.00% | -25,348.75% | -264,333.33% | -3,452.00% | -6,189.51% |
| Total Other Income/Expenses | 678.49K | 437.75K | 372.41K | 1.51K | 81.05K | 143.50K | -322.63K | -2.15M | -2.42M | -3.06M | -1.28M | -526.00K | -64.00K |
| Income Before Tax | -30.16M | -30.95M | -38.70M | -27.40M | -14.26M | -16.74M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -18.94M |
| Income Before Tax Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,210.49% |
| Income Tax Expense | 0.00 | -437.75M | -369.89K | -163.07K | -160.72K | 10.23M | -7.17M | 86.00K | 10.00K | 1.08M | 1.49M | 567.00K | 0.00 |
| Net Income | -30.16M | -30.95M | -38.33M | -27.40M | -14.26M | -26.97M | -11.50M | -39.31M | -39.59M | -23.34M | -17.14M | -22.10M | -19.56M |
| Net Income Ratio | -1,074.17% | -309.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,131.20% | 0.00% | -29,177.50% | -285,716.67% | -3,536.16% | -6,414.10% |
| EPS | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| EPS Diluted | -4.15 | -4.39 | -7.52 | -10.93 | -10.99 | -30.16 | -3.56 | -14.18 | -15.57 | -16.04 | -9.02 | -280.83 | -267.41 |
| Weighted Avg Shares Out | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.21K | 2.54M | 1.45M | 1.90M | 78.70K | 73.16K |
| Weighted Avg Shares Out (Dil) | 7.28M | 7.05M | 5.10M | 2.51M | 1.30M | 894.37K | 269.36K | 69.58K | 0.00 | 1.45M | 1.90M | 78.70K | 73.16K |
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
This overlooked corner of women's health could be a $350 billion market opportunity
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
Source: https://incomestatements.info
Category: Stock Reports